Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent

Cancer Cell International

Volumn 12, Issue , 2012, Pages

  Alajez, Nehad M ^a,b   Mocanu, Joseph D ^b,c   Krushel, Tiffany ^b,c   Bell, John C ^d,e   Liu, Fei Fei ^b,c,f,g  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g 610 University Avenue   (Canada)

Author keywords

HNSCC; Oncolytic virus; Radiotherapy; Vascular disrupting

Indexed keywords

N ACETYLCOLCHINOL PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MOUSE; NONHUMAN; TUMOR XENOGRAFT; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION;

EID: 84862195847     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-12-27     Document Type: Article

References (22)

1. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008, 83(4):489-501. 10.4065/83.4.489, 18380996.
2. Giralt J, Benavente S, Arguis M. Optimizing approaches to head and neck cancer: strengths and weaknesses in multidisciplinary treatments of locally advanced disease. Ann Oncol 2008, 19(Suppl 7):vii195-199.
3. Bell JC, Lichty B, Stojdl D. Getting oncolytic virus therapies off the ground. Cancer Cell 2003, 4(1):7-11. 10.1016/S1535-6108(03)00170-3, 12892708.
4. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19(6):1008-1016.
5. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4(4):263-275. 10.1016/S1535-6108(03)00241-1, 14585354.
6. Moussavi M, Fazli L, Tearle H, Guo Y, Cox M, Bell J, Ong C, Jia W, Rennie PS. Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res 2010, 70(4):1367-1376. 10.1158/0008-5472.CAN-09-2377, 20145134.
7. Alain T, Lun X, Martineau Y, Sean P, Pulendran B, Petroulakis E, Zemp FJ, Lemay CG, Roy D, Bell JC, et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad 2010, 107(4):1576-1581.
8. Alajez NM, Mocanu JD, Shi W, Chia MC, Breitbach CJ, Hui AB, Knowles S, Bell JC, Busson P, Takada K, et al. Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma. Clin Cancer Res 2008, 14(15):4891-4897. 10.1158/1078-0432.CCR-07-4134, 18676763.
9. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002, 54(5):1497-1502. 10.1016/S0360-3016(02)03922-6, 12459377.
10. Schepelmann S, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Chen P, Marais R, Springer CJ. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res 2007, 67(10):4949-4955. 10.1158/0008-5472.CAN-07-0297, 17510425.
11. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009, 69(23):8932-8940. 10.1158/0008-5472.CAN-08-3873, 2789204, 19920199.
12. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 7362:99-102.
13. Advani SJ, Markert JM, Sood RF, Samuel S, Gillespie GY, Shao MY, Roizman B, Weichselbaum RR. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther 11:1098-1102.
14. Gaddy DF, Lyles DS. Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol 2007, 81(6):2792-2804. 10.1128/JVI.01760-06, 1865982, 17192316.
15. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007, 15(9):1686-1693. 10.1038/sj.mt.6300215, 17579581.
16. Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WK, Alemany R, Fueyo J. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 2007, 14(8):756-761. 10.1038/sj.cgt.7701067, 17557108.
17. Diallo JS, Boeuf FL, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, Mactavish H, Waite K, Falls T, Wang J, et al. A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. Mol Ther 2010, 18(6):1123-1129. 10.1038/mt.2010.67, 2889739, 20389287.
18. Mocanu JD, Yip KW, Alajez NM, Shi W, Li JH, Lunt SJ, Moriyama EH, Wilson BC, Milosevic M, Lo KW, et al. Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. Mol Ther 2007, 15(5):921-929.
19. Mocanu JD, Yip KW, Skliarenko J, Shi W, Busson P, Lo KW, Bastianutto C, Liu FF. Imaging and modulating antisense microdistribution in solid human xenograft tumor models. Clin Cancer Res 2007, 13(19):5935-5941. 10.1158/1078-0432.CCR-06-3085, 17908990.
20. Alajez NM, Shi W, Hui AB, Yue S, Ng R, Lo KW, Bastianutto C, O'Sullivan B, Gullane P, Liu FF. Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy. Cell Death Differ 2009, 16(11):1469-1479. 10.1038/cdd.2009.85, 19575017.
21. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, et al. miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway. Cancer Res 2011, 71(6):2381-2391. 10.1158/0008-5472.CAN-10-2754, 21385904.
22. Trotter MJ, Chaplin DJ, Durand RE, Olive PL. The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys 1989, 16(4):931-934. 10.1016/0360-3016(89)90889-4, 2703399.